We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $28.39, moving -6.7% from the previous trading session. This change lagged the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw a downswing of 0.68%, while the tech-heavy Nasdaq depreciated by 1.13%.
The company's shares have seen a decrease of 4.16% over the last month, not keeping up with the Medical sector's loss of 3.03% and the S&P 500's gain of 1.26%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. The company is predicted to post an EPS of $0.07, indicating a 16.67% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $893.37 million, reflecting a 49.15% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.79 per share and a revenue of $3.22 billion, demonstrating changes of -249.06% and +37.03%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 55% lower. Hims & Hers Health, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 84, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS - Free Report) closed the most recent trading day at $28.39, moving -6.7% from the previous trading session. This change lagged the S&P 500's daily loss of 0.76%. Elsewhere, the Dow saw a downswing of 0.68%, while the tech-heavy Nasdaq depreciated by 1.13%.
The company's shares have seen a decrease of 4.16% over the last month, not keeping up with the Medical sector's loss of 3.03% and the S&P 500's gain of 1.26%.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. The company is predicted to post an EPS of $0.07, indicating a 16.67% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $893.37 million, reflecting a 49.15% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.79 per share and a revenue of $3.22 billion, demonstrating changes of -249.06% and +37.03%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 55% lower. Hims & Hers Health, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 84, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.